Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease
To compare the efficacy, patient-reported satisfaction, and safety of preservative-free (PF)-tafluprost, PF-dorzolamide/timolol and preservative-containing (P)-latanoprost in Korean glaucoma patients with ocular surface disease (OSD). In a multicenter, prospective, interventional, non-randomized, co...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/2/201 |
| _version_ | 1827653271590797312 |
|---|---|
| author | Sang-Woo Park Jiwoong Lee Michael S. Kook |
| author_facet | Sang-Woo Park Jiwoong Lee Michael S. Kook |
| author_sort | Sang-Woo Park |
| collection | DOAJ |
| description | To compare the efficacy, patient-reported satisfaction, and safety of preservative-free (PF)-tafluprost, PF-dorzolamide/timolol and preservative-containing (P)-latanoprost in Korean glaucoma patients with ocular surface disease (OSD). In a multicenter, prospective, interventional, non-randomized, controlled 12-week trial, 107 eligible patients received PF-tafluprost (<i>n</i> = 37), PF-dorzolamide/timolol (<i>n</i> = 34), or P-latanoprost eye drops (<i>n</i> = 36). Outcomes included changes from baseline in OSD Index (OSDI) scores (primary endpoint), intraocular pressure (IOP), and patient-reported treatment satisfaction, and safety at 12 weeks. At 12 weeks, the mean total OSDI and subdomain (dry eye symptoms, visual-related function, environmental triggers) scores significantly improved from baseline with PF-tafluprost and PF-dorzolamide/timolol, but not with P-latanoprost. Significantly more PF-tafluprost than P-latanoprost recipients reported ‘highly improved/improved’ satisfaction (no significant difference between PF-dorzolamide/timolol and P-latanoprost). IOP changes were comparable among all three treatment groups. No new safety concerns were observed. PF-tafluprost and PF-dorzolamide/timolol showed statistically and clinically significant reductions in OSDI compared with P-latanoprost in Korean glaucoma patients with OSD. |
| first_indexed | 2024-03-09T21:15:37Z |
| format | Article |
| id | doaj.art-197c8e3e81f94bf5933b9d1aff495b05 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T21:15:37Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-197c8e3e81f94bf5933b9d1aff495b052023-11-23T21:34:38ZengMDPI AGPharmaceuticals1424-82472022-02-0115220110.3390/ph15020201Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface DiseaseSang-Woo Park0Jiwoong Lee1Michael S. Kook2Chonnam National University Hospital, Gwangju 61469, KoreaPusan National University Hospital, Busan 49241, KoreaDepartment of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, KoreaTo compare the efficacy, patient-reported satisfaction, and safety of preservative-free (PF)-tafluprost, PF-dorzolamide/timolol and preservative-containing (P)-latanoprost in Korean glaucoma patients with ocular surface disease (OSD). In a multicenter, prospective, interventional, non-randomized, controlled 12-week trial, 107 eligible patients received PF-tafluprost (<i>n</i> = 37), PF-dorzolamide/timolol (<i>n</i> = 34), or P-latanoprost eye drops (<i>n</i> = 36). Outcomes included changes from baseline in OSD Index (OSDI) scores (primary endpoint), intraocular pressure (IOP), and patient-reported treatment satisfaction, and safety at 12 weeks. At 12 weeks, the mean total OSDI and subdomain (dry eye symptoms, visual-related function, environmental triggers) scores significantly improved from baseline with PF-tafluprost and PF-dorzolamide/timolol, but not with P-latanoprost. Significantly more PF-tafluprost than P-latanoprost recipients reported ‘highly improved/improved’ satisfaction (no significant difference between PF-dorzolamide/timolol and P-latanoprost). IOP changes were comparable among all three treatment groups. No new safety concerns were observed. PF-tafluprost and PF-dorzolamide/timolol showed statistically and clinically significant reductions in OSDI compared with P-latanoprost in Korean glaucoma patients with OSD.https://www.mdpi.com/1424-8247/15/2/201dorzolamide/timololglaucomaP-latanoprostocular surface diseasepreservative-freetafluprost |
| spellingShingle | Sang-Woo Park Jiwoong Lee Michael S. Kook Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease Pharmaceuticals dorzolamide/timolol glaucoma P-latanoprost ocular surface disease preservative-free tafluprost |
| title | Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease |
| title_full | Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease |
| title_fullStr | Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease |
| title_full_unstemmed | Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease |
| title_short | Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease |
| title_sort | efficacy safety and patient reported outcomes with preservative free pf tafluprost or pf dorzolamide timolol compared with preserved latanoprost a prospective multicenter study in korean glaucoma patients with ocular surface disease |
| topic | dorzolamide/timolol glaucoma P-latanoprost ocular surface disease preservative-free tafluprost |
| url | https://www.mdpi.com/1424-8247/15/2/201 |
| work_keys_str_mv | AT sangwoopark efficacysafetyandpatientreportedoutcomeswithpreservativefreepftafluprostorpfdorzolamidetimololcomparedwithpreservedlatanoprostaprospectivemulticenterstudyinkoreanglaucomapatientswithocularsurfacedisease AT jiwoonglee efficacysafetyandpatientreportedoutcomeswithpreservativefreepftafluprostorpfdorzolamidetimololcomparedwithpreservedlatanoprostaprospectivemulticenterstudyinkoreanglaucomapatientswithocularsurfacedisease AT michaelskook efficacysafetyandpatientreportedoutcomeswithpreservativefreepftafluprostorpfdorzolamidetimololcomparedwithpreservedlatanoprostaprospectivemulticenterstudyinkoreanglaucomapatientswithocularsurfacedisease |